Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

(2012) Edith A. Perez et al.   MAYO CLINIC PROCEEDINGS

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

(2010) Dominika Nowis et al.   AMERICAN JOURNAL OF PATHOLOGY

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24

(2010) R. Goodwin et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Emerging Anticancer Therapeutic Targets and the Cardiovascular System

(2010) Xuyang Peng et al.   CIRCULATION RESEARCH

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

The Vulnerability of the Heart As a Pluricellular Paracrine Organ

(2010) Gilles W. De Keulenaer et al.   CIRCULATION RESEARCH

Development of a Drug Screening Platform Based on Engineered Heart Tissue

(2010) Arne Hansen et al.   CIRCULATION RESEARCH

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

(2010) Vishnu Chintalgattu et al.   JOURNAL OF CLINICAL INVESTIGATION

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Intricacies of Bevacizumab-Induced Toxicities and Their Management

(2009) Sarah M Gressett et al.   ANNALS OF PHARMACOTHERAPY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

(2009) Hassane Izzedine et al.   EUROPEAN JOURNAL OF CANCER

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

(2009) Stephen Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the ubiquitin system in cancer therapy

(2009) Daniela Hoeller et al.   NATURE

Evidence for Cardiomyocyte Renewal in Humans

(2009) Olaf Bergmann et al.   SCIENCE

Twice upon a time: PI3K's secret double life exposed

(2009) Emilio Hirsch et al.   TRENDS IN BIOCHEMICAL SCIENCES

The role of autophagy in the heart

(2008) K Nishida et al.   CELL DEATH AND DIFFERENTIATION

Autophagy in Load-Induced Heart Disease

(2008) Beverly A. Rothermel et al.   CIRCULATION RESEARCH

Cardiotoxicity Profile of Trastuzumab

(2008) Steven M Ewer et al.   DRUG SAFETY

Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork?

(2008) Daniel J. Lenihan   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?

(2008) Michael S. Ewer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

(2008) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY